Humacyte HUMA
NASDAQ HUMA
$0.41 0.00 (-0.34%)
As of: Oct 22, 2026 · 10:58 AM EDT

Humacyte (HUMA) EBITDA Margin (2020 - 2026)

Updated

Humacyte's EBITDA Margin was -6319.95% in Q2 2026, up 3124.24 percentage points from -9444.19% a year earlier but down 745.61 percentage points from the prior quarter.

Analysis

Humacyte (HUMA) EBITDA Margin (2020 - 2026) Analysis & Trends

On a trailing twelve-month basis, Humacyte's EBITDA Margin was -4990.57% through Jun 30, 2026, up 7974.83 percentage points year-over-year; for FY2025, it was -5044.60%.

  • Quarterly EBITDA Margin has moved between -9444.19% (Q2 2025) and -3066.40% (Q3 2025) over five years.
  • Per Business Quant data, HUMA's EBITDA Margin in the three quarters before Q2 2026 was -5574.34% (Q1 2026), -6318.63% (Q4 2025) and -3066.40% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,167.56 Bn 1,136.14 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 635.76 Bn 554.29 Bn 17.26 Bn 35.95%
3 AbbVie 503.27 Bn 476.38 Bn 12.70 Bn 49.01%
4 Merck 377.51 Bn 331.89 Bn 12.21 Bn 6.02%
5 Novartis Ag 304.07 Bn 268.06 Bn 11.24 Bn -
6 Astrazeneca 267.53 Bn 241.22 Bn 12.86 Bn 33.11%
7 Amgen 242.06 Bn 197.46 Bn 7.24 Bn 46.01%
8 Gilead Sciences 194.26 Bn 168.46 Bn 6.22 Bn -124.26%
9 Pfizer 172.62 Bn 119.27 Bn 10.94 Bn 39.16%
10 Humacyte 96.16 Mn -102.28 Mn -825,000.00 -6,209.36%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -6,209.36%
Mar 31, 2026 -5,483.84%
Dec 31, 2025 -6,222.91%
Sep 30, 2025 -2,996.81%
Jun 30, 2025 -9,270.43%
Mar 31, 2025 -4,133.08%
Sep 30, 2021 -7,687.97%
Sep 30, 2020 -1,708.21%
API Access

Humacyte EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=HUMA&period=max&api_key=YOUR_API_KEY